Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison

被引：0
|
作者：
Ma, C. [1 ]
Dubinsky, M. C. [2 ]
Axelrad, J. [3 ]
Anyanwu, S. [4 ]
Tran, J. [5 ,6 ]
Lacerda, A. [4 ]
Joshi, N. [4 ]
Griffith, J. [4 ]
机构：
[1] Univ Calgary, Dept Med, Inflammatory Bowel Dis Clin, Calgary, AB, Canada
[2] Icahn Sch Med Mt Sinai, Div Pediat Gastroenterol & Nutr, New York, NY USA
[3] NYU Grossman Sch Med, Div Gastroenterol, Dept Med, New York, NY USA
[4] AbbVie Inc, Chicago, IL USA
[5] AbbVie Inc, Seattle, WA USA
[6] Univ Washington, Comparat Hlth Outcomes Policy & Econ Inst, Seattle, WA USA
来源：
JOURNAL OF CROHNS & COLITIS | 2024年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P1040
引用
收藏
页码：I1866 / I1867
页数：2
相关论文
共 50 条
  • [1] Comparative effectiveness of upadacitinib versus ustekinumab in patients with moderately to severely active Crohn's disease: a matching-adjusted indirect comparison
    Thin, Lena
    Ma, Christopher
    Dubinsky, Marla
    Axelrad, Jordan
    Anyanwu, Samuel
    Tran, Jacinda
    Lacerda, Ana
    Joshi, Namita
    Griffith, Jenny
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2024, 39 : 156 - 157
  • [2] Comparative efficacy and safety of upadacitinib versus ustekinumab as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    Reinisch, W.
    Panaccione, R.
    Duijvestein, M.
    Santos, D. Ceballos
    Melmed, G. Y.
    Xuan, S.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 672 - 672
  • [3] Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn's Disease
    Dubinsky, Marla
    Ma, Christopher
    Griffith, Jenny
    Crowell, Marjorie
    Neimark, Ezequiel
    Kligys, Kristina
    O'Connell, Tom
    ADVANCES IN THERAPY, 2023, 40 (09) : 3896 - 3911
  • [4] Matching-Adjusted Indirect Comparison Between Risankizumab and Ustekinumab for Induction and Maintenance Treatment of Moderately to Severely Active Crohn’s Disease
    Marla Dubinsky
    Christopher Ma
    Jenny Griffith
    Marjorie Crowell
    Ezequiel Neimark
    Kristina Kligys
    Tom O’Connell
    Advances in Therapy, 2023, 40 : 3896 - 3911
  • [5] Matching-Adjusted Indirect Comparison of Upadacitinib versus Vedolizumab as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis
    Reinisch, Walter
    Vermeire, Severine
    Hedin, Charlotte
    Rubin, David T.
    Panes, Julian
    Deng, Huiwen
    Xuan, Si
    Wegrzyn, Lani
    Liu, John
    Ilo, Dapo
    Zhou, Wen
    Sanchez-Gonzalez, Yuri
    Panaccione, Remo
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S520 - S521
  • [6] COMPARATIVE EFFICACY AND SAFETY OF UPADACITINIB VERSUS TOFACITINIB AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A MATCHING-ADJUSTED INDIRECT COMPARISON
    Reinisch, Walter
    Tran, Jacinda N.
    Patel, Kamal V.
    Borruel, Natalia
    Melmed, Gil
    Wegrzyn, Lani R.
    Levy, Gweneth
    Ilo, Dapo
    Gonzalez, Yuri Sanchez
    Panaccione, Remo
    GASTROENTEROLOGY, 2023, 164 (06) : S650 - S651
  • [7] Comparative Efficacy and Safety of Upadacitinib Versus Tofacitinib as Induction Therapy in Patients With Moderately to Severely Active Ulcerative Colitis: A Matching-Adjusted Indirect Comparison
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, G. Y.
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF CROHNS & COLITIS, 2023, 17 : 785 - 786
  • [8] A matching-adjusted indirect comparison (MAIC) of vedolizumab vs risankizumab in patients with moderately-to-severely active Crohn's disease
    Jairath, V
    Dulai, P. S.
    Talsma, P.
    Wu, J. J.
    Adsul, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : i1959 - i1961
  • [9] Matching-adjusted indirect comparison of upadacitinib vs vedolizumab as induction therapy in patients with moderately to severely active ulcerative colitis
    Venugopal, K.
    Reinisch, W.
    Vermeire, S.
    Hedin, C.
    Rubin, D. T.
    Panes, J.
    Deng, H.
    Xuan, S.
    Wegrzyn, L.
    Liu, J.
    Ilo, D.
    Zhou, W.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 135 - 135
  • [10] Comparative efficacy and safety of upadacitinib vs tofacitinib as induction therapy in patients with moderately to severely active ulcerative colitis: A matching-adjusted indirect comparison
    An, Y-K
    Reinisch, W.
    Tran, J.
    Patel, K.
    Borruel, N.
    Melmed, Gy
    Wegrzyn, L.
    Levy, G.
    Ilo, D.
    Gonzalez, Y. Sanchez
    Panaccione, R.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2023, 38 : 128 - 129
12345